Cancer Vaccine Efforts Get Boost
In May, the chancellors of Â鶹ӳ» and Texas A&M Systems signed an agreement to combine resources in creating the National Center for Therapeutic Manufacturing (NCTM), a state-of-the-art biological pharmaceutical manufacturing facility, being constructed on the A&M campus.
Through this agreement, MD Anderson will become a long-term partner and collaborator of the NCTM, increasing the ability of researchers from its laboratories to quickly provide important new cancer vaccines and treatments, including vaccines targeted to specific people.
¡°More than 30 potential new drugs devised at MD Anderson are in clinical trials or poised to enter clinical trials, and using this new facility will improve our drug-making efficiency tremendously, as well as lower the cost,¡± says Provost and Executive Vice President Raymond DuBois, M.D., Ph.D.
